Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco
- PMID: 20548786
- PMCID: PMC2883572
- DOI: 10.1371/journal.pone.0011068
Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco
Abstract
Background: At the individual level, higher HIV viral load predicts sexual transmission risk. We evaluated San Francisco's community viral load (CVL) as a population level marker of HIV transmission risk. We hypothesized that the decrease in CVL in San Francisco from 2004-2008, corresponding with increased rates of HIV testing, antiretroviral therapy (ART) coverage and effectiveness, and population-level virologic suppression, would be associated with a reduction in new HIV infections.
Methodology/principal findings: We used San Francisco's HIV/AIDS surveillance system to examine the trends in CVL. Mean CVL was calculated as the mean of the most recent viral load of all reported HIV-positive individuals in a particular community. Total CVL was defined as the sum of the most recent viral loads of all HIV-positive individuals in a particular community. We used Poisson models with robust standard errors to assess the relationships between the mean and total CVL and the primary outcome: annual numbers of newly diagnosed HIV cases. Both mean and total CVL decreased from 2004-2008 and were accompanied by decreases in new HIV diagnoses from 798 (2004) to 434 (2008). The mean (p = 0.003) and total CVL (p = 0.002) were significantly associated with new HIV cases from 2004-2008.
Conclusions/significance: Reductions in CVL are associated with decreased HIV infections. Results suggest that wide-scale ART could reduce HIV transmission at the population level. Because CVL is temporally upstream of new HIV infections, jurisdictions should consider adding CVL to routine HIV surveillance to track the epidemic, allocate resources, and to evaluate the effectiveness of HIV prevention and treatment efforts.
Conflict of interest statement
Figures




Similar articles
-
Use of the community viral load as a population-based biomarker of HIV burden.AIDS. 2012 Jan 28;26(3):345-53. doi: 10.1097/QAD.0b013e32834de5fe. AIDS. 2012. PMID: 22008660
-
Modelling the dynamics of population viral load measures under HIV treatment as prevention.Infect Dis Model. 2018 Sep 21;3:160-170. doi: 10.1016/j.idm.2018.09.001. eCollection 2018. Infect Dis Model. 2018. PMID: 30839936 Free PMC article.
-
Reduced community viral load does not coincide with a reduction in the rate of new HIV diagnoses and recent infections: data from a region of southern Italy.HIV Med. 2017 Nov;18(10):711-723. doi: 10.1111/hiv.12515. Epub 2017 Apr 26. HIV Med. 2017. PMID: 28444818
-
Reduction in HIV community viral loads following the implementation of a "Treatment as Prevention" strategy over 2 years at a population-level among men who have sex with men in Hangzhou, China.BMC Infect Dis. 2018 Feb 1;18(1):62. doi: 10.1186/s12879-017-2927-2. BMC Infect Dis. 2018. PMID: 29390979 Free PMC article.
-
AIDS epidemic in San Francisco among men who report sex with men: successes and challenges of HIV prevention.J Acquir Immune Defic Syndr Hum Retrovirol. 1997;14 Suppl 2:S38-46. doi: 10.1097/00042560-199700002-00008. J Acquir Immune Defic Syndr Hum Retrovirol. 1997. PMID: 9070513 Review.
Cited by
-
Ten year trends in community HIV viral load in Barbados: implications for treatment as prevention.PLoS One. 2013;8(3):e58590. doi: 10.1371/journal.pone.0058590. Epub 2013 Mar 8. PLoS One. 2013. PMID: 23520523 Free PMC article.
-
Retention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid dependent released prisoners.PLoS One. 2012;7(5):e38335. doi: 10.1371/journal.pone.0038335. Epub 2012 May 31. PLoS One. 2012. PMID: 22719814 Free PMC article.
-
Measuring the unknown: calculating community viral load among HIV-infected MSM unaware of their HIV status in San Francisco from National HIV Behavioral Surveillance, 2004-2011.J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):e84-6. doi: 10.1097/QAI.0b013e31828ed2e4. J Acquir Immune Defic Syndr. 2013. PMID: 23666144 Free PMC article. No abstract available.
-
Assessment of population-based HIV RNA levels in a rural east African setting using a fingerprick-based blood collection method.Clin Infect Dis. 2013 Feb;56(4):598-605. doi: 10.1093/cid/cis881. Epub 2012 Dec 12. Clin Infect Dis. 2013. PMID: 23243180 Free PMC article.
-
Tailored treatment for HIV+ persons with mental illness: the intervention cascade.J Acquir Immune Defic Syndr. 2013 Jun 1;63 Suppl 1(0 1):S44-8. doi: 10.1097/QAI.0b013e318293067b. J Acquir Immune Defic Syndr. 2013. PMID: 23673886 Free PMC article. Review.
References
-
- Garcia PM, Kalish LA, Pitt J, Minkoff H, Quinn TC, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med. 1999;341:394–402. - PubMed
-
- HIV testing and prophylaxis to prevent mother-to-child transmission in the United States. Pediatrics. 2008;122:1127–1134. - PubMed
-
- Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. 2002;29:484–494. - PubMed
-
- Dickover RE, Garratty EM, Herman SA, Sim MS, Plaeger S, et al. Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission. Effect of maternal zidovudine treatment on viral load. Jama. 1996;275:599–605. - PubMed
-
- Mofenson LM, Lambert JS, Stiehm ER, Bethel J, Meyer WA, 3rd, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med. 1999;341:385–393. - PubMed